Bookmark and Share

Sanford A Stass
 

Sanford A Stass M.D.

Academic Title: Professor
Primary Appointment: Pathology
Secondary Appointments: Medical and Research Technology, Medicine
Administrative Title: Chair, Department Of Pathology
sstass@som.umaryland.edu
Location: MSTF 734
Phone: 410-706-7070
Phone: 410-328-1237
Fax: 410-328-1813

Personal History:

B.A. – University of California at Los Angeles
M.D. – University of Missouri

Diplomate, National Board of Medical Examiners
Diplomate, American Board of Pathology, Anatomic & Clinical
Diplomate, American Board of Pathology, Hematopathology

Research Interests:

A major area of Dr. Stass' research investigation involves the molecular biology/genetic changes in cancer, hematopoietic neoplasia, and biomarkers in cancer. His basic research program has provided the basis for translational research, i.e., transfer of research into the clinic.

Dr. Stass is recognized nationally and internationally for his research in the molecular biology of hematopoietic neoplasia. He has published over 190 peer-reviewed articles. He is recognized for major contributions in the molecular biology and immunologic characterizations of leukemias and lymphomas, including identification and clinical application of novel biomarkers for diagnosis, prognosis, and therapeutic monitoring. He was the first to describe the t(1;19)(q23;p13) abnormality in pre-B ALL (Cell) and the first to amplify a chromosomal translocation (t14;18)(132;q21) as a biomarker to detect minimal residual disease in lymphoma (Science) and one of the first to amplify the bcr-abl transcript as a marker to detect minimal residual disease in chronic myeloid leukemia (Blood). Dr. Stass was also among the first to delineate the heterogeneity of acute leukemias (acute mixed lineage and lineage switch leukemia) important in defining markers of lineage commitment for appropriate therapy.

Dr. Stass has extensive experience in biomarker development and validation and, as PI on an NIH/NCI funded grant (University of Maryland Baltimore Biomarker Research Laboratory). He is working toward the development and testing of promising new cancer biomarkers using innovative technologies with application in a certified diagnostic laboratory environment.


Publications:

Chen, Q.R., Zhang, L., Stass, S.A., & Mixson, A.J. Co-polymer of histidine and lysine markedly enhances transfection of liposomes. Gene Ther. 7: 1698-1705, 2000.

Chen, Q.R., Zhang, L., Stass, S.A., & Mixson, A.J. Branched co-polymers of histidine and lysine are efficient carriers of plasmids. Nucleic Acids Res. Mar 15; 29(6):1334-40, 2001.

Zhang, L., Gasper, W.J., Stass, S.A., Ioffe, O.B., Davis, M.A., & Mixson, A.J. Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res (Oct 1); 62(19): 5463-9, 2002.

Selaru, F.M., Yin, J., Olaru, A., Mori, Y., Xu, Y., Epstein, S.H., Sato, F., Deacu, E., Wang, S., Sterian, A., Fulton, A., Abraham, J.M., Shibata, D., Baquet, C., Stass, S.A., & Meltzer, S.J. An unsupervised approach to identify molecular phenotypic components influencing breast cancer features. Cancer Res, 64:1584-1588, 2004.

Sato, F., Shimada, Y., Selaru, F., Shibata, D., Maeda, M., Watanabe, G., Mori, Y., Stass, S., Imamura, M., & Meltzer, S.: Prediction of survival in patients with esophageal carcinoma using artificial neural networks. Cancer; Apr; 1596-1605, 2005.

Li, R., Wang, H., Yin, Z., Caraway, N.P., Katz, R.L., Stass, S.A., & Jiang, F. Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach. Oncogene, 25(18):2628-35, 2006.